For patients facing a cancer diagnosis, the financial dimension of care can feel as overwhelming as the medical one. In the United States, the average cost of cancer treatment in the first year after diagnosis often exceeds $150,000, according to data from the National Cancer Institute. In many European countries, out-of-pocket expenses for innovative therapies like immunotherapy can still reach tens of thousands of euros. This is why a growing number of international patients are exploring cancer treatment in China, where modern oncology—including immunotherapy and PD-1 inhibitors—is available at a fraction of Western prices.
But what does the total cost actually include? This article breaks down the components you should expect when planning oncology care in China, from consultations to medication, hospitalization, and follow-up. All figures are given in USD and reflect typical ranges reported by international departments at major Chinese hospitals and by patients in communities such as Reddit's r/medicaltourism. Prices vary by hospital, city, and individual case.
Understanding the Cost Components
When you receive a treatment quote from a Chinese hospital, it is rarely a single lump sum. Instead, costs are itemized. The table below outlines the main components, typical unit prices or ranges, and notes on minimum quantities or additional fees.
| Component | Typical Unit Price (USD) | Minimum Quantity / Notes |
|---|---|---|
| Initial specialist consultation | $50 – $200 per visit | Usually 2–3 visits for treatment planning |
| Diagnostic imaging (CT, MRI, PET-CT) | $200 – $1,200 per scan | PET-CT at the higher end; may require multiple scans |
| Laboratory tests (blood, pathology, genomics) | $100 – $2,500 | Genomic sequencing (NGS) for targeted therapy can cost $1,500–$2,500 |
| Surgery (e.g., lung cancer resection) | $8,000 – $18,000 | Includes surgeon, anesthesia, OR, standard hospitalization |
| Chemotherapy (per cycle) | $500 – $2,000 | 4–6 cycles typical; varies by drug regimen |
| Immunotherapy (PD-1 inhibitor, per cycle) | $3,500 – $5,500 | Keytruda (pembrolizumab) and domestic PD-1s available; 2–3 cycles minimum before assessment |
| Targeted therapy (oral TKI, per month) | $1,000 – $3,000 | EGFR TKIs for NSCLC; often continued for 12+ months |
| Hospitalization (per day, general ward) | $80 – $250 | Private rooms can be $300–$600 per day |
| Intensive care (per day, if needed) | $800 – $2,000 | Only if complications arise |
| Medical records translation | $100 – $300 | Certified translation for continuity of care |
| Medical interpreter (per day) | $80 – $150 | Essential for consultations and consent |
| Recovery stay (post-discharge, per day) | $100 – $200 | Medical-grade accommodation with nursing visits |
| Follow-up imaging and labs (first year) | $500 – $1,500 | Every 3–6 months after treatment |
Note: These ranges are indicative and based on publicly available data from Chinese hospital international departments, patient forums, and published cost comparisons. Actual quotes depend on the specific hospital, city, and complexity of your case.
Per-Component Details
1. Consultations and Second Opinions
Before traveling, many patients obtain a remote second opinion from a Chinese oncologist. This service, offered by platforms like SSAnkang, allows you to have your pathology slides and imaging reviewed without leaving home. A remote second opinion typically costs $200–$500, depending on the hospital and the complexity of the case. In-person consultations in China range from $50 to $200 for a specialist at a top-tier hospital such as the Chinese PLA General Hospital (301 Hospital) in Beijing or Shanghai Changhai Hospital. These initial visits are crucial for staging and treatment planning.
2. Diagnostic Imaging and Laboratory Tests
Accurate staging is the foundation of effective cancer treatment. In China, a PET-CT scan—often essential for detecting metastases—costs between $800 and $1,200, compared to $3,000–$6,000 in the US. MRI and CT scans are $200–$600 each. Genomic testing (next-generation sequencing) to identify actionable mutations like EGFR, ALK, or ROS1 typically costs $1,500–$2,500. This is a one-time expense that guides the choice of targeted therapies.
3. Surgery
For solid tumors, surgery remains the primary curative option. At major Chinese hospitals, a lung cancer resection (lobectomy) costs $8,000–$18,000, including surgeon fees, anesthesia, operating room, and standard hospital stay. This is roughly 30–50% of the average US price. For example, a patient from the United States with Stage IIIA EGFR-positive non-small cell lung cancer paid $22,000–$35,000 for surgery plus adjuvant TKI therapy at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS). This covered a 75-day treatment period and resulted in no evidence of disease at 18 months. While individual outcomes vary, this case illustrates the potential cost savings without compromising on comprehensive care.
4. Chemotherapy
Chemotherapy costs in China are significantly lower than in Western countries. A single cycle of platinum-based chemotherapy for lung cancer costs $500–$2,000. A typical regimen of 4–6 cycles would therefore total $2,000–$12,000. These prices include the drugs, administration, and related supportive care. Domestic generic chemotherapies are widely available and have been used in Chinese hospitals for decades.
5. Immunotherapy and PD-1 Inhibitors
Immunotherapy has revolutionized cancer treatment, and China is a global leader in both the use and production of PD-1 inhibitors. Keytruda (pembrolizumab), the most widely known PD-1 inhibitor, costs $3,500–$5,500 per cycle in China—roughly 40–60% of the US list price of about $10,000 per cycle. In addition to imported Keytruda, China has several domestically developed PD-1 inhibitors (such as toripalimab, sintilimab, and camrelizumab) that are often even more affordable, with per-cycle costs starting around $2,000–$3,500. These domestic options have been approved by China's National Medical Products Administration (NMPA) and are used for melanoma, non-small cell lung cancer, head-and-neck cancers, and others.
A typical course of immunotherapy may involve 2–3 cycles before a response assessment, and then continuation for up to 2 years. So the total immunotherapy cost could range from $10,000 to $60,000 depending on the drug, duration, and whether it is combined with other treatments. It is important to discuss with your oncologist whether a domestic or imported PD-1 inhibitor is appropriate for your specific cancer type and biomarker profile.
6. Targeted Therapy
For patients with actionable mutations, oral targeted therapies (TKIs) are taken daily. In China, a month's supply of first-generation EGFR TKIs (like gefitinib or erlotinib) costs $1,000–$2,000. Third-generation osimertinib (Tagrisso) is more expensive, at $2,500–$3,000 per month. However, these prices are still lower than in the US, where osimertinib costs around $15,000 per month without insurance. Patients from the US case mentioned earlier received adjuvant TKI therapy as part of their $22,000–$35,000 total, which included surgery and follow-up.
7. Hospitalization and Supportive Care
General ward hospitalization in Chinese hospitals costs $80–$250 per day. Private rooms, often available in international departments, range from $300 to $600 per day. Intensive care, if needed, is $800–$2,000 per day. Most surgical stays are 5–10 days, while chemotherapy or immunotherapy cycles may require 1–3 days per cycle. Supportive care—such as anti-nausea drugs, growth factors, and pain management—is usually included in the per-cycle cost but can add a few hundred dollars.
8. Additional Services: Translation, Interpretation, and Recovery
For international patients, language and logistics can add 10–20% to the total cost. Medical records translation is $100–$300 and is often required before a hospital will schedule treatment. A medical interpreter costs $80–$150 per day; many patients hire one for the initial consultation and consent process. Post-discharge, a recovery stay in medical-grade accommodation with nursing visits costs $100–$200 per day for 1–3 weeks. SSAnkang offers tiered support packages: Basic (free) includes online consultation and appointment booking; Gold ($599) adds a 5-day interpreter, airport pickup, visa support, and accommodation booking; Diamond ($2,499) provides a full-trip interpreter, 24/7 case manager, premium accommodation, local transport, records translation, and 12-month remote follow-up. These services are optional but can greatly reduce stress.
Landed Cost Comparison
To estimate your total landed cost, add up the components relevant to your treatment plan. Here is a rough comparison for a typical lung cancer patient requiring surgery plus adjuvant targeted therapy (similar to the case described above):
- United States: Surgery $40,000–$80,000; 12 months of TKI $180,000; imaging and labs $10,000–$20,000; consultations $5,000. Total: $235,000–$285,000 (before insurance).
- China (top-tier hospital): Surgery $8,000–$18,000; 12 months of TKI $12,000–$36,000; imaging and labs $3,000–$5,000; consultations $500–$1,000; translation and interpretation $1,000–$2,000; recovery stay $2,000–$4,000. Total: $26,500–$66,000.
Even with premium support services, the total cost in China is typically 30–60% lower than in the US. For immunotherapy alone, a 12-month course of Keytruda in China would cost $42,000–$66,000, versus $120,000–$180,000 in the US.
These figures are estimates. Your actual cost depends on your specific diagnosis, treatment protocol, hospital choice, and length of stay. To get a personalized estimate, you can submit your medical records for a remote second opinion. SSAnkang Medical can help you connect with leading Chinese oncology hospitals such as the Cancer Hospital of CAMS, 301 Hospital, and Shanghai Changhai Hospital, and provide a transparent cost breakdown before you commit to travel. For more information, visit our oncology services page or speak with a case manager.
Disclaimer: This article is for informational purposes only and does not constitute medical or financial advice. Always consult with qualified healthcare providers before making treatment decisions.